Which role for brexpiprazole, a new dopamine D2 partial agonist, in the treatment of schizophrenia?

Comment

Leslie Citrome. Evid Based Ment Health. 2016 May.

. 2016 May;19(2):e6.

doi: 10.1136/eb-2015-102143. Epub 2016 Apr 5.

No abstract available

Comment on

Efficacy and Safety of Brexpiprazole for the Treatment of Acute Schizophrenia: A 6-Week Randomized, Double-Blind, Placebo-Controlled Trial.
Correll CU, Skuban A, Ouyang J, Hobart M, Pfister S, McQuade RD, Nyilas M, Carson WH, Sanchez R, Eriksson H. Correll CU, et al. Am J Psychiatry. 2015 Sep 1;172(9):870-80. doi: 10.1176/appi.ajp.2015.14101275. Epub 2015 Apr 16. Am J Psychiatry. 2015. PMID: 25882325 Clinical Trial.

1. Citrome L, Stensbøl TB, Maeda K. The preclinical profile of brexpiprazole: what is its clinical relevance for the treatment of psychiatric disorders? Expert Rev Neurother 2015;15:1219–29. - PubMed
1. Citrome L. Brexpiprazole for schizophrenia and as adjunct for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antipsychotic—what is the number needed to treat, number needed to harm and likelihood to be helped or harmed? Int J Clin Pract 2015;69:978–97. 10.1111/ijcp.12714 - DOI - PubMed
1. Kane JM, Skuban A, Ouyang J, et al. . A multicenter, randomized, double-blind, controlled phase 3 trial of fixed-dose brexpiprazole for the treatment of adults with acute schizophrenia. Schizophr Res 2015;164:127–35. 10.1016/j.schres.2015.01.038 - DOI - PubMed
1. Citrome L. The ABC's of dopamine receptor partial agonists—aripiprazole, brexpiprazole and cariprazine: the 15-min challenge to sort these agents out. Int J Clin Pract. 2015;69:1211–20. 10.1111/ijcp.12752 - DOI - PubMed